ClinVar Miner

Submissions for variant NM_000090.4(COL3A1):c.1024G>A (p.Gly342Arg)

dbSNP: rs794728040
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 6
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
GeneDx RCV000505729 SCV000233352 pathogenic not provided 2024-12-28 criteria provided, single submitter clinical testing Not observed at significant frequency in large population cohorts (gnomAD); Occurs in the triple helical domain and replaces the glycine in the canonical Gly-X-Y repeat; missense substitution of a canonical glycine residue is expected to disrupt normal protein folding and function, and this is an established mechanism of disease (HGMD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 31126764, 9036918, 10706896))
CeGaT Center for Human Genetics Tuebingen RCV000505729 SCV001153218 likely pathogenic not provided 2019-06-01 criteria provided, single submitter clinical testing
Labcorp Genetics (formerly Invitae), Labcorp RCV001051687 SCV001215855 likely pathogenic Ehlers-Danlos syndrome, type 4 2023-06-24 criteria provided, single submitter clinical testing In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. This variant disrupts the triple helix domain of COL3A1. Glycine residues within the Gly-Xaa-Yaa repeats of the triple helix domain are required for the structure and stability of fibrillar collagens (PMID: 7695699, 8218237, 19344236). In COL3A1, variants that affect these glycine residues are significantly enriched in individuals with disease (PMID: 24922459, 25758994) compared to the general population (ExAC). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt COL3A1 protein function. ClinVar contains an entry for this variant (Variation ID: 199715). This missense change has been observed in individual(s) with clinical features of Ehlers-Danlos syndrome (PMID: 31126764). This variant is not present in population databases (gnomAD no frequency). This sequence change replaces glycine, which is neutral and non-polar, with arginine, which is basic and polar, at codon 342 of the COL3A1 protein (p.Gly342Arg).
CHEO Genetics Diagnostic Laboratory, Children's Hospital of Eastern Ontario RCV001170887 SCV001333511 likely pathogenic Familial thoracic aortic aneurysm and aortic dissection 2018-09-14 criteria provided, single submitter clinical testing
Ambry Genetics RCV001170887 SCV002692834 likely pathogenic Familial thoracic aortic aneurysm and aortic dissection 2024-04-22 criteria provided, single submitter clinical testing The p.G342R variant (also known as c.1024G>A), located in coding exon 15 of the COL3A1 gene, results from a G to A substitution at nucleotide position 1024. The glycine at codon 342 is replaced by arginine, an amino acid with dissimilar properties. The majority (approximately two-thirds) of COL3A1 mutations identified to date have involved the substitution of another amino acid for glycine within the triple-helical domain (Pepin MG et al. Genet Med. 2014;16(12):881-8; Frank M et al. Eur J Hum Genet. 2015;23(12):1657-64). This variant was reported in individuals with features consistent with vascular Ehlers-Danlos syndrome (Kluivers KB et al. Int Urogynecol J Pelvic Floor Dysfunct, 2009 Sep;20:1113-8; Shalhub S et al. J Vasc Surg, 2019 11;70:1543-1554). Internal structural analysis indicates that this alteration disrupts the characteristic G-X-Y motif in the COL3A1 protein and inserts a bulky side chain into a sterically-constrained region (Bella J et al. Science. 1994;266:75-81; Hohenester E et al. Proc. Natl. Acad. Sci. U.S.A. 2008;105:18273-7; Ambry internal data). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). Based on the majority of available evidence to date, this variant is likely to be pathogenic.
Mayo Clinic Laboratories, Mayo Clinic RCV000505729 SCV005413538 pathogenic not provided 2023-12-07 criteria provided, single submitter clinical testing PP2, PP3, PP4, PM1_strong, PM2, PS4_moderate

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.